Human Metabolome Technologies (TSE:6090) Cyclically Adjusted PS Ratio: (As of Aug. 03, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TSE:6090 Human Metabolome Technologies Inc TSE:6090
59 GF Score
Price 円591.00
GF Value 円531.46
Valuation Modestly Overvalued
! 4 Warning Signs
View Full Analysis

What is Human Metabolome Technologies Cyclically Adjusted PS Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Human Metabolome Technologies  (TSE:6090) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Human Metabolome Technologies Cyclically Adjusted PS Ratio Related Terms


Human Metabolome Technologies Cyclically Adjusted PS Ratio Historical Data

* Premium members only.

The historical data trend for Human Metabolome Technologies's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Human Metabolome Technologies Cyclically Adjusted PS Ratio Chart

Human Metabolome Technologies Annual Data
Trend Mar15 Mar16 Mar17 Mar18 Mar19 Jun20 Jun21 Jun22 Jun23 Jun24
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 4.15 3.27

Human Metabolome Technologies Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.27 3.73 3.62 0.00 0.00

TSE:6090 vs TMO, DHR, IDXX: Cyclically Adjusted PS Ratio Comparison

For the Diagnostics & Research subindustry, Human Metabolome Technologies's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Human Metabolome Technologies Cyclically Adjusted PS Ratio vs Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Human Metabolome Technologies's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Human Metabolome Technologies's Cyclically Adjusted PS Ratio falls into.


TSE:6090
59GF Score
Human Metabolome Technologies Inc TSE:6090
Cyclically Adjusted PS Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Human Metabolome Technologies Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Human Metabolome Technologies's Cyclically Adjusted Revenue per Share for the quarter that ended in Dec. 2025 is calculated as:

For example, Human Metabolome Technologies's adjusted Revenue per Share data for the three months ended in Dec. 2025 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Dec. 2025 (Change)*Current CPI (Dec. 2025)
=0/113.0000*113.0000
=0.000

Current CPI (Dec. 2025) = 113.0000.

Human Metabolome Technologies Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201512 28.366 98.100 32.674
201603 61.798 97.900 71.330
201606 17.166 98.100 19.773
201609 31.175 98.000 35.947
201612 40.835 98.400 46.894
201703 69.556 98.100 80.121
201706 20.232 98.500 23.210
201709 32.665 98.800 37.360
201712 36.493 99.400 41.486
201803 71.744 99.200 81.725
201806 25.842 99.200 29.437
201809 21.461 99.900 24.275
201812 27.727 99.700 31.426
201903 67.588 99.700 76.604
201906 0.000 99.800 0.000
201909 33.883 100.100 38.250
201912 43.731 100.500 49.170
202003 91.816 100.300 103.442
202006 21.242 99.900 24.027
202009 41.675 99.900 47.140
202012 49.478 99.300 56.304
202103 65.931 99.900 74.577
202106 33.485 99.500 38.028
202109 29.411 100.100 33.201
202112 61.046 100.100 68.913
202203 80.744 101.100 90.248
202206 36.117 101.800 40.091
202209 44.489 103.100 48.761
202212 58.917 104.100 63.954
202303 78.682 104.400 85.163
202306 37.912 105.200 40.723
202309 39.824 106.200 42.374
202312 67.218 106.800 71.120
202403 81.585 107.200 85.999
202406 38.897 108.200 40.623
202412 0.000 110.700 0.000
202503 98.509 111.100 100.194
202506 32.123 111.700 32.497
202509 33.863 112.000 34.165
202512 0.000 113.000 0.000

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

Is Human Metabolome Technologies (TSE:6090) Overvalued in 2026?

Based on GuruFocus' analysis, Human Metabolome Technologies stock appears to be overvalued. The current stock price of 円591.00 is trading 11.2% above its estimated GF Value™ of 円531.46. GuruFocus considers Human Metabolome Technologies to be Modestly Overvalued.

Key valuation signals for TSE:6090:

  • Cyclically Adjusted PS Ratio:
  • GF Value™: 円531.46 vs. price of 円591.00 (11.2% above fair value)
  • GF Score™: 59/100 with 4 warning signs

No single metric tells the full story. See the TSE:6090 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Human Metabolome Technologies Business Description

Address Yamagata Prefecture Kakuganji Water 246-2, Tsuruoka, JPN, 997-0052
Human Metabolome Technologies Inc is involved in the search and diagnosis of biomarkers and commercialization in the field of drug development.
59GF Score

Get the complete analysis for TSE:6090

Cyclically Adjusted PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

円591.00
Price
円531.46
GF Value